Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

(NASDAQ:AMRX) BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval o...

What upside or downside risk does the Q4 2025 product launch present for AMRX’s stock price given potential competition and supply constraints? How much market share can Amneal realistically capture from Janssen’s Risperdal Consta in the next 12‑18 months? What is the expected revenue uplift from the 180‑day CGT exclusivity period and how will it affect AMRX’s valuation?
Symbol: AMRX
Drug approval
6 days ago
Read more globenewswire

Indaptus Therapeutics Provides Clinical Update

(IDPT) Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases

Will this data point lead to a re‑rating of the stock or trigger any partnership or licensing activity? How does the observed response compare to existing therapies for urothelial cancer and potential market share? What does this partial response mean for the progression of INDPT's Decoy20 program and potential FDA filing timeline?
Symbol: IDPT
Clinical trials
6 days ago
Read more globenewswire

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

(NASDAQ:MLYS) RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How might the full exercise of the underwriters’ option to purchase additional shares impact the stock’s price and trading volume in the short term? What is the intended allocation of the proceeds and how will it influence upcoming clinical milestones or partnership opportunities? How will the $287.5 million capital raise affect Mineralys’ cash runway and dilution?
Symbol: MLYS
Capital
6 days ago
Read more globenewswire

CSG Announces Contract Extension With Charter Communications

(NASDAQ:CSGS) DENVER--(BUSINESS WIRE)--CSGÂź (NASDAQ: CSGS) and Charter Communications today announce that they have signed a multi-year contract extension and expansion of their decades-long relati...

What potential risks or upside does the expanded scope of services for Charter present, and how might the market price‑reaction reflect changes in CSG’s growth trajectory and valuation multiples? What are the financial terms of the extension (contract value, annual revenue contribution, profit margins) and how do they compare to CSG’s existing contracts and to similar agreements held by competitors? How will the extended multi‑year contract with Charter affect CSG’s revenue guidance and earnings per share outlook for the next fiscal year?
Symbol: CSGS
Contracts
6 days ago
Read more businesswire

Lumen Technologies, Inc. Announces [Upsize and] Pricing of its Additional 7.000% First Lien Notes Due 2034

(NYSE:LUMN) DENVER--(BUSINESS WIRE)--Lumen Technologies, Inc. (“Lumen”, “us,” “we” or “our”) (NYSE: LUMN) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. (“Level 3 Financi...

What immediate impact might this additional issuance have on Lumen’s stock liquidity and short‑term price volatility? How does the pricing of the upsized 7.0% First Lien Notes compare to existing Lumen debt and comparable telecom issuances? What is the intended use of the $425 million proceeds and how will it affect Lumen’s leverage ratios?
Symbol: LUMN
Financing
6 days ago
Read more businesswire